STOCK TITAN

Elicio Therapeutics, Inc. - ELTX STOCK NEWS

Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.

Elicio Therapeutics, Inc. (ELTX) is a clinical-stage biotechnology company pioneering lymph node-targeted immunotherapies through its proprietary AMP platform. This dedicated news hub provides investors and industry observers with timely updates on ELTX's progress in developing novel cancer treatments.

Access official press releases, clinical trial milestones, and corporate developments related to ELTX's innovative pipeline. Track updates on KRAS-targeted vaccines, AMP platform advancements, and strategic collaborations. Our curated collection includes regulatory filings, peer-reviewed research highlights, and financial disclosures essential for informed analysis.

Key focus areas include clinical progress updates, partnership announcements, intellectual property developments, and scientific presentations. This resource serves investors seeking to monitor ELTX's position in the competitive immunotherapy landscape while staying informed about its novel approach to enhancing T cell responses against aggressive cancers.

Bookmark this page for streamlined access to verified ELTX developments. Check regularly for updates on the company's mission to transform cancer treatment through precision immune system engagement.

Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced that its CEO and EVP will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference. The chat will be accessible via RSVP to a B. Riley Securities sales representative and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (ELTX) announces the dosing of the first patient in the Phase 2 study of ELI-002 7P, a therapeutic cancer vaccine targeting seven common mutations in KRAS, at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research. The vaccine aims to treat pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. Elicio's proprietary AMP technology targets more mutations compared to other KRAS-targeted therapies, potentially benefiting a larger patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced promising results from the Phase 1 study of ELI-002 in Nature Medicine, demonstrating robust, polyfunctional, and durable KRAS-specific CD4+ and CD8+ T cell responses in cancer patients. The study showed an 84% reduction in tumor biomarkers, correlating with a median relapse-free survival of 16.3 months. A Phase 2 trial for ELI-002 in pancreatic ductal adenocarcinoma is planned to start in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.31%
Tags
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) has entered into a subscription agreement to sell 1,213,000 shares of its common stock at a purchase price of $5.81 per share in a private placement to GKCC, LLC, controlled by a member of Elicio’s Board of Directors. The gross proceeds of the private placement are expected to be approximately $7.0 million, with the net proceeds intended for the advancement of its development pipeline, as well as for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.21%
Tags
none
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) will present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on December 6, 2023. The company is a clinical-stage biotechnology firm focusing on developing immunotherapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.04%
Tags
conferences
-
Rhea-AI Summary
ELTX: Elicio Therapeutics reports promising results for ELI-002 in pancreatic cancer treatment. Median relapse-free survival of 16.3 months and a significant reduction in risk of progression or death. Plans to initiate ELI-002 7P Phase 2 trial in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
Rhea-AI Summary
Elicio Therapeutics announces promising data from the Phase 1 study of ELI-002 cancer vaccine in patients with mKRAS-driven pancreatic and colorectal cancers. 87% of patients had mKRAS-specific T cell responses and the strength of the response correlated with reduced risk of relapse and death. ELI-007 and ELI-008 vaccines also showed strong induction of tumor-antigen-specific T cell responses in mice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.06%
Tags
-
Rhea-AI Summary
Elicio Therapeutics to present updated data on ELI-002 and preclinical data on ELI-007 and ELI-008 at SITC 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences
-
Rhea-AI Summary
Elicio Therapeutics announces promising preliminary relapse-free survival data for its cancer vaccine ELI-002. Preliminary data from the Phase 1 study shows an 86% reduction in the risk of progression or death in patients with large T cell responses. Elicio plans to initiate a randomized Phase 2 study in early 2024. No safety concerns were identified.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
Rhea-AI Summary
Elicio Therapeutics receives $2.6M grant for cancer vaccine research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
none
Elicio Therapeutics, Inc.

Nasdaq:ELTX

ELTX Rankings

ELTX Stock Data

75.94M
9.02M
43.86%
7.16%
1.34%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON